BACKGROUND: Alemtuzumab (ALEM) is a humanised monoclonal antibody that depletes circulating lymphocytes by selectively targeting CD52, which is expressed in high levels on T- and B-lymphocytes. This depletion is followed by lymphocyte repopulation and a cytokine expression shift towards a lesser inflammatory profile, both of which may contribute to prolonged efficacy. National recommendations for enrolling and treating multiple sclerosis (MS) patients with ALEM have been established. However, there are no recommendations in place for the treatment of MS reactivation after the ALEM treatment. OBJECTIVES: To evaluate the effectiveness and safety of the use of ALEM and to analyse subsequent disease-modifying treatments (DMTs). A multidimensional prediction model was developed to make a patient-specific prognosis regarding the response to ALEM. DESIGN: A multicentre, prospective, non-controlled, non-interventional, observational cohort study. METHODS: Relapsing multiple sclerosis patients (RMSp) who received ⩾1 dose of ALEM were enrolled. In each treatment year, the following baseline and prospective data were collected: age, MS history, number, type and duration of previous disease-modifying treatment (PDMT), relapse rate (REL), expanded disability status scale (EDSS), magnetic resonance imaging and serious adverse events (AE). In cases of reactivation of MS, all data about the subsequent DMT were collected. RESULTS: A total of 142 RMSp from 10 MS Slovak Centres fulfilled the inclusion criteria. The average age was 35 years (standard error 8.56). The overall average EDSS was 3.87 (1.46) when ALEM was started. The average duration of PDMT was 6.0 (4.04) years, and the median number of PDMTs was 3 (0-5), while the patients were mostly treated with 2 or 3 DMTs (>65.00%). Post-ALEM treatment was needed in 39 cases (27.46%). The most frequent post-ALEM treatment indicated was ocrelizumab, followed by natalizumab (NAT), siponimod and cladribine. The ocrelizumab and NAT treatment bring little benefit to patients. Siponimod showed less EDSS increase in contrast to ocrelizumab and NAT. Another repopulation therapy, cladribine, may also be an effective option. Statistically significant predictors for the expected EDSS are age (p-value <0.0001), number of ALEM cycles (0.0066), high number of PDMT (0.0459) and the occurrence of relapses (<0.0001). There was no statistically significant effect on the patient's gender (0.6038), duration of disease-modifying treatment before alemtuzumab (0.4466), or the occurrence of AE (0.6668). CONCLUSION: The study confirms the positive effect of ALEM on clinical and radiological outcomes. We need more data from long-term sequencing studies.

1 Clinic of Neurology Comenius University in Bratislava Bratislava Slovakia

2 Clinic of Neurology Comenius University in Bratislava Bratislava Slovakia

Biomedical Centre Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovakia

Clinic of Neurology F D Roosevelt University Hospital in Banská Bystrica Banská Bystrica Slovakia

Clinic of Neurology Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Mala hora 4 Martin 036 01 Slovakia

Clinic of Neurology Jessenius Faculty of Medicine in Martin Comenius University in Bratislava Martin Slovakia

Clinic of Neurology Pavol Jozef Šafárik University in Košice Košice Slovakia

Clinic of Neurology Trnava University in Trnava Slovakia

Clinic of Neurology University Hospital in Trencˇín Trencˇín Slovakia

Clinic of Neurology University Hospital Nitra Nitra Slovakia

Clinic of Neurology University of Prešov Prešov Slovakia

Department of Neurology Military Hospital Ružomberok Ružomberok Slovakia

Department of Probability and Mathematical Statistics Faculty of Mathematics and Physics Charles University Prague Czech Republic

Zobrazit více v PubMed

Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. J Neurol Neuroimmunol Neuroinflamm 2020; 7: e636. PubMed PMC

Filippi M, Bar-Or A, Piehl F, et al.. Multiple sclerosis. Nat Rev Dis Prim 2018; 4(1): 43. PubMed

Giovannoni G, Lang S, Wolff R, et al.. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther 2020; 9(2): 359–374. PubMed PMC

Montalban X, Gold R, Thompson AJ, et al.. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018; 24(2): 96–120. PubMed

Ontaneda D, Tallantyre EC, Raza PC, et al.. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials 2020; 95: 106009. PubMed

Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol 2018; 31: 233–243. PubMed

Filippi M, Amato MP, Centonze D, et al.. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 2022; 269(10): 5382–5394. PubMed PMC

Berger T, Elovaara I, Fredrikson S, et al.. Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs 2017; 31(1): 33–50. PubMed PMC

Cox AL, Thompson SA, Jones JL, et al.. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35(11): 3332–3342. PubMed

Havari E, Turner MJ, Campos-Rivera J, et al.. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology 2014; 141(1): 123–131. PubMed PMC

U.S. Food and Drug Administration (FDA). Lemtrada prescribing information, http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf (accessed 14 November 2014).

European Medicines Agency. Lemtrada article 20 procedure – measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada, First published 04 August 2021, https://www.ema.europa.eu/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-seriousside-effects-multiple-sclerosis_en-0.pdf (Last accessed 19 July 2022).

European Medicines Agency (EMA). Lemtrada. Summary of product characteristics (SmPC), First published 25 September 2013, https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada#product-information-section (Last accessed 22 April 2024).

Meca-Lallana JE, Álvarez-Cermeño JC, Casanova Estruch B, et al.. Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study. Neurología 2023; 39(5): 383–391. PubMed

López-Real AM, Gonzalez I, Solar DM, et al.. Alemtuzumab treatment in real clinical practice: experience in a multicenter cohort. Mult Scler Relat Disord 2023; 75: 104762. PubMed

Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. 1st ed. New York: Springer, 2000.

R Core Team. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2022.

Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017; 10(10): 343–359. PubMed PMC

Russo CV, Saccà F, Frau J, et al.. A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol 2022; 29(1): 257–266. PubMed PMC

Coles AJ, Cohen JA, Fox EJ, et al.. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 2017; 89(11): 1117–1126. PubMed PMC

Havrdova E, Douglas DL, Cohen JA, et al.. Alemtuzumab CARE-MS I 5-year follow-up. Durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89(11): 1107–1116. PubMed PMC

Van Wijmeersch B, Singer BA, Boster A, et al.. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: post hoc analysis of the CARE-MS studies. Mult Scler 2020; 26(13): 1719–1728. PubMed PMC

Ziemssen T, Bass AD, Berkovich R, et al.. Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs 2020; 34: 973–988. PubMed PMC

Berger T, Adamczyk-Sowa M, Csépány T, et al.. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers, and burden of disease. Ther Adv Neurol Disord 2020; 13: 1756286420975223. PubMed PMC

Tuohy O, Costelloe L, HillCawthorne G, et al.. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86: 208–215. PubMed

Puthenparampil M, Gaggiola M, Miscioscia A, et al.. Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis. Ther Adv Neurol Disord 2023; 16: 17562864231177196. PubMed PMC

Grand’Maison F, Yeung M, Morrow SA, et al.. Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural Regen Res 2018; 13(11): 1871–1874. PubMed PMC

Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21: 22–34. PubMed PMC

Vališ M, Ryška P, Halúsková S, et al.. Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy. BMC Neurol 2020; 20(1): 202. PubMed PMC

Adamec I, Habek M. Ocrelizumab for post-alemtuzumab paradoxical disease activity in highly active multiple sclerosis. Clin Neuropharmacol 2022; 45(5): 139–141. PubMed

Lapucci C, Frau J, Cocco E, et al.. Short-term evaluation of alemtuzumab to ocrelizumab switch in MS patients with disease activity after alemtuzumab: an Italian multicentric study. Mult Scler J 2020; 26(3): 195–196.

Horáková D, Boster A, Bertolotto A, et al.. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Mult Scler J Exp Transl Clin 2020; 6(4): 2055217320972137. PubMed PMC

Lorscheider J, Buzzard K, Jokubaitis V, et al.. Defining secondary progressive multiple sclerosis. Brain 2016; 139(Pt 9): 2395–2405. PubMed

Kappos L, Belachew S, Butzkueven H, et al.. Long-term safety and efficacy and association between baseline treatment history and post-baseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI Observational Program (TOP). Neurology 2012; 78(Suppl): 1.

Hanna J, Rosen JP, Smethurst C. Efficacy and safety of treatment with natalizumab for relapsing-remitting multiple sclerosis: interim results of the Tysabri Observational Programme in the UK. J Neurol Neurosurg Psychiatry 2013; 84: e2.

Kinnunen T, Chamberlain N, Morbach H, et al.. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2013; 121: 1595–1603. PubMed PMC

Castilho JL, Bian A, Jenkins CA, et al.. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the international epidemiology databases to evaluate AIDS (IeDEA). CD4/CD8 ratio and cancer risk among adults with HIV. J Natl Cancer Inst 2022; 114(6): 854–862. PubMed PMC

Mellergård J, Edström M, Jenmalm MC, et al.. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients. PLoS One 2013; 8(12): e81685. PubMed PMC

Kashani N, Kelland EE, Vajdi B, et al.. Immune regulatory cell bias following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Front Immunol 2021; 12: 706278. PubMed PMC

Adamec I, Jovanović I, Krbot Skorić M, et al.. Double immune reconstitution therapy: cladribine after alemtuzumab in the treatment of multiple sclerosis. Eur J Neurol 2022; 29(3): 901–904. PubMed

Sorensen PS, Pontieri L, Joensen H, et al.. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study. Mult Scler Relat Disord 2023; 70: 104491. PubMed

Kantorová E, Vajdová V, Hnilicová P, et al.. Cystic echinococcosis causing thrombosis of the inferior vena cava in a patient with multiple sclerosis treated with alemtuzumab. Ther Adv Neurol Disord 2020; 13:1756286420954081. doi: 10.1177/1756286420954081. PubMed DOI PMC

Boffa G, Sbragia E, Raiola AM, et al.. Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: a report of three cases. Mult Scler 2021; 27(7): 1145–1148. PubMed